Alnylam Pharmaceuticals has appointed Phil Davey as Country Manager for the United Kingdom and Ireland, taking over the newly created global role within Alnylam from Brendan Martin, who has taken over as Senior Vice President of Commercial Innovation Lead.
Davey has over 18 years of senior position experience in the biotechnology and pharmaceutical industries, during which he has played both regional and regional roles in the United States and the United Kingdom. He joined Alnylam from Alexion Pharmaceuticals and has led the company’s solidification business for the past seven years, most recently as Vice President of Business Unit Leads.
Davie commented on his appointment, stating: “We are pleased to join Alnylam as Country Manager in the United Kingdom and Ireland. Alnylam is committed to transforming RNA interference (RNAi) technology into a new class of innovative therapies for patients with rare diseases. Offers the long-awaited treatment options and has the potential to change the outcome. I work with this strong team to continue this commitment to patients, with the growth of the current UK portfolio and its rarity. We are excited to promote a first-in-class pipeline of new drugs for the more common patients in the UK and Ireland as a whole. “
Kasha Witkos, Senior Vice President of International Affairs at Alnylam, said: , And clinical practice, which in and of itself play an important role in our global and international operations. We are honored to welcome Phil to Alnylam. We are confident that his dynamic leadership, vision, and outstanding track record of patient change will bring great value to our business and help build our reputation and leadership in RNAi. We look forward to continued growth, development and prosperity of our UK and Irish businesses and teams under Phil’s leadership. “
Alnylam Pharmaceuticals Appoints New Country Managers for UK and Ireland
Source link Alnylam Pharmaceuticals Appoints New Country Managers for UK and Ireland